Online inquiry

IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9824MR)

This product GTTS-WQ9824MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets BTLA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001085357.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 151888
UniProt ID Q7Z6A9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9824MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6038MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ3721MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ7321MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ13417MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ14162MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ4129MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ15840MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ13704MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW